Evidence map›Paper›PMID 33773553›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

Thymoquinone Suppresses Cell Proliferation and Enhances Apoptosis of HL60 Leukemia Cells through Re-Expression of JAK/STAT Negative Regulators.

Belal Almajali, Hamid Ali Nagi Al-Jamal, Wan Rohani Wan Taib, Imilia Ismail, Muhammad Farid Johan, Abd Almonem Doolaanea, Wisam Nabeel Ibrahim, Syed Ahmad Tajudin

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Molecular & cellular oncology · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Therapeutic effect of some natural active compounds for breast cancer.Medical oncology (Northwood, London, England) · 2022
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Belal AlmajaliSchool of Biomedicine, Faculty of Health Sciences, Universiti Sultan Zainal Abidin (UniSZA), 20300 Terengganu, Malaysia.
Hamid Ali Nagi Al-JamalSchool of Biomedicine, Faculty of Health Sciences, Universiti Sultan Zainal Abidin (UniSZA), 20300 Terengganu, Malaysia.ORCID 0000-0001-6194-2729
Wan Rohani Wan TaibSchool of Biomedicine, Faculty of Health Sciences, Universiti Sultan Zainal Abidin (UniSZA), 20300 Terengganu, Malaysia.
Imilia IsmailSchool of Biomedicine, Faculty of Health Sciences, Universiti Sultan Zainal Abidin (UniSZA), 20300 Terengganu, Malaysia.ORCID 0000-0002-3701-4006
Muhammad Farid JohanDepartment of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.ORCID 0000-0001-6344-0220
Abd Almonem DoolaaneaPharmaceutical Technology Department, Faculty of pharmacy, International Islamic University Malaysia, Kuantan, Malaysia.
Wisam Nabeel IbrahimDepartment of Biomedical Sciences, Collage of Health sciences, QU Health, Qatar University, Doha, Qatar.
Syed Ahmad TajudinCentralized Laboratory Management Centre, Universiti Sultan Zainal Abidin, 22200 Besut, Terengganu, Malaysia.
Universiti Sains Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe natural compound, thymoquinone (TQ) has demonstrated potential anticancer properties in inhibiting cell proliferation and promoting apoptosis in myeloid leukemia cells, breast cancer cells, and others. However, the effect mechanism of TQ on AML cells still not fully understood. In this study, the authors examined the effects of TQ on the expression of JAK/STAT-negative regulator genes SOCS-1, SOCS-3, and SHP-1, and their consequences on cell proliferation and apoptosis in HL60 leukemia cells.

methodsMTT and trypan blue exclusion tests were conducted to determine the 50% inhibitory concentration (IC50) and cell proliferation. FITC Annexin and Guava® reagent were used to study the cell apoptosis and examine the cell cycle phases, respectively. The expression of JAK/STAT-negative regulator genes, SOCS-1, SOCS-3, and SHP-1, was investigated using reverse transcriptase- quantitative PCR (RT-qPCR).

resultsTQ demonstrated a potential inhibition of HL60 cell proliferation and a significant increase in apoptotic cells in dose and time-dependent manner. TQ significantly induced cycle arrest at G0-G1 phase (P < 0.001) and enhanced the re-expression of JAK/STAT-negative regulator genes.

conclusionTQ potentially inhibited HL60 cell proliferation and significantly increased apoptosis with re-expression of JAK/STAT-negative regulator genes suggesting that TQ could be a new therapeutic candidate for leukemia therapy.<br />.

Indexed as

ApoptosisBenzoquinonesCell ProliferationHL-60 CellsHumansInhibitory Concentration 50Janus KinasesLeukemia, Promyelocytic, AcuteProtein Tyrosine Phosphatase, Non-Receptor Type 6STAT Transcription FactorsSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling 3 ProteinBenzoquinonesJanus KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 6PTPN6 protein, humanSOCS1 protein, humanSOCS3 protein, humanSTAT Transcription FactorsSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling 3 ProteinthymoquinoneJAK/STAT signalingLeukemianegative regulatorsthymoquinone

Identifiers

PMID33773553
PMCPMC8286695
OpenAlexW3150865211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.